FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* TANANBAUM JAMES B					2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]									k all applicab Director	all applicable)		g Person(s) to Issuer 10% Owner Other (specify		
(Last) 435 TAS SUITE 2	SO STREE	First) T	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/18/2006									below)		below)		респу	
(Street) PALO A	LTO (CA CA	94301		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)																
			Table I - Non	-Deriva	tive	Sec	urities A	cquired	, Di	sposed	of, or B	enefic	cially C	wned					
1. Title of Security (Instr. 3)		[2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Disp		urities Acquired (A) or sed Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Follo	.	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A)) or F	rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock								С		2,366,6	655 ⁽²⁾	A (1)		2,366,655(2)		I		See Footnote ⁽⁵⁾	
Common Stock		04/18/2006				С		36,04	40 ⁽²⁾ A (1)		(1)	36,040(2)		I		ee cootnote ⁽⁶⁾			
			Table II - I				rities Aco , warrant							vned					
Security or Exercis (Instr. 3) Price of	Conversion or Exercise Price of Derivative	rcise (Month/Day/Year) of tive	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Securities Underlyin Derivative Security (3 and 4)		ying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou Numb Share	er of		(Instr. 4)				
Series B Preferred Stock	(1)	04/18/2006		С			7,833,056	(3)		(4)	Common Stock	2,366	5,655 ⁽²⁾	(1)	0		I	See Footnote ⁽⁵⁾	
Series B Preferred	(1)	04/18/2006		С			119,286	(3)		(4)	Common Stock	36,	040(2)	(1)	0		I	See Footpote ⁽⁶⁾	

Explanation of Responses:

- 1. Reflects the automatic conversion of each share of Series B Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial
- 2. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
- 3. Immediately
- 4. Not Applicable
- 5. Shares are held of record by Prospect Venture Partners II, L.P. The reporting person serves as a managing member of Prospect Management Co. II, L.L.C., the general partner of Prospect Venture Partners II, L.P. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any
- 6. Shares are held of record by Prospect Associates II, L.P. The reporting person serves as a managing member of Prospect Management Co. II, L.L.C., the general partner of Prospect Associates II, L.P. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose

04/18/2006 /s/ James B. Tananbaum, M.D.

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.